Loading...
Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
BACKGROUND: A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the drugs in combination therapy has not yet been reported. CASE PRESENTATION: A...
Saved in:
| Published in: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7041078/ https://ncbi.nlm.nih.gov/pubmed/32093631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6626-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|